|
influenza |
26 |
|
covid-19 |
17 |
|
influenza virus |
16 |
|
universal vaccine |
16 |
|
vaccination |
15 |
|
antibody |
13 |
|
immunity |
13 |
|
t cells |
13 |
|
acute lung injury |
9 |
|
alveolar fluid clearance |
9 |
|
avian |
9 |
|
coronavac |
9 |
|
mesenchymal stromal cells |
9 |
|
public health |
9 |
|
vaccine |
9 |
|
aged |
8 |
|
antibodies |
8 |
|
antibody-dependent cellular cytotoxicity |
8 |
|
baseline immunity |
8 |
|
ha stem antibodies |
8 |
|
heterosubtypic immunity |
8 |
|
influenza virus infection |
8 |
|
universal immune correlate |
8 |
|
adolescent |
7 |
|
adult |
7 |
|
betacoronavirus |
7 |
|
blood |
7 |
|
cell-mediated immunity |
7 |
|
coronavirus infection |
7 |
|
omicron |
7 |
|
cd8+ t cells |
6 |
|
coronavirus disease 2019 |
6 |
|
elisa |
6 |
|
hla-b*15:01 |
6 |
|
immunogenicity |
6 |
|
intradermal |
6 |
|
severe disease |
6 |
|
t cell |
6 |
|
t cell receptors |
6 |
|
2019 novel coronavirus disease |
5 |
|
adcc |
5 |
|
adjuvant |
5 |
|
b cell |
5 |
|
c-type lectins |
5 |
|
clec5a |
5 |
|
deubiquitylases |
5 |
|
ha stem |
5 |
|
hong kong |
5 |
|
infection |
5 |
|
innate immune response |
5 |
|
macrophages |
5 |
|
rig-i signaling |
5 |
|
rna virus |
5 |
|
sars-cov-2 |
5 |
|
spleen tyrosine kinase (syk) |
5 |
|
ubiquitylation |
5 |
|
clinical trials |
4 |
|
hemagglutinin-stalk |
4 |
|
il-15 |
4 |
|
mouse-adaptation |
4 |
|
next-generation sequencing |
4 |
|
nk cells |
4 |
|
universal vaccines |
4 |
|
vaccinia |
4 |
|
broadly neutralizing epitopes |
3 |
|
chimeric hemagglutinin |
3 |
|
durable b cell responses |
3 |
|
ha anchor epitope |
3 |
|
ha stalk epitope |
3 |
|
influenza lineage elimination |
3 |
|
long covid |
3 |
|
next-generation influenza vaccine |
3 |
|
sars-cov-2 epitopes |
3 |
|
seasonal influenza |
3 |
|
short- and long-term evolutionary dynamics |
3 |
|
universal influenza vaccine |
3 |
|
2009 h1n1 influenza |
2 |
|
antibody blood level |
2 |
|
antibody titer |
2 |
|
antibody vaccine |
2 |
|
b lymphocyte |
2 |
|
broad-spectrum vaccine |
2 |
|
disease x |
2 |
|
enzyme linked immunosorbent assay |
2 |
|
passive immunization |
2 |
|
peptide-mapping |
2 |
|
ring vaccination |
2 |
|
adaptive immunity |
1 |
|
adults |
1 |
|
antigenic variation |
1 |
|
b7 allelic family |
1 |
|
cd4 t lymphocytes + |
1 |
|
cd8 t cells + |
1 |
|
cd8 t cells + |
1 |
|
cd8t cells |
1 |
|
cytotoxic t cells |
1 |
|
elderly |
1 |
|
epitope-specific cd8+ t cells |
1 |
|
h1n1 2009 |
1 |
|
hepatitis c virus |
1 |
|
human cd8+ t cells |
1 |
|
influenza a virus |
1 |
|
influenza infection |
1 |
|
influenza viruses |
1 |
|
innate immunity |
1 |
|
lipopeptide vaccination |
1 |
|
liver |
1 |
|
longevity |
1 |
|
mouse b6 model |
1 |
|
np418-426 variants |
1 |
|
pmhc tetramers |
1 |
|
repertoire |
1 |
|
t cell memory |
1 |
|
t cells memory |
1 |
|
t-cell receptor |
1 |
|
t-cell receptor repertoire |
1 |
|
t-cell receptors |
1 |
|
t-cell responses |
1 |
|
tcr |
1 |
|
tcr repertoire |
1 |
|
vaccine design |
1 |
|
viral escape mechanisms |
1 |
|
viral infection |
1 |
